The combination of GLP-1 receptor agonist peptides and BPC-157 is a subject of interest in research communities, driven by a specific mechanistic hypothesis: that BPC-157’s gastrointestinal and tissue biology effects may address some of the side effects and body composition concerns associated with GLP-1R agonist use.